Canadian lab explains puzzling link between semaglutide, better liver health

Researchers at Toronto’s Sinai Health have uncovered new insights into how glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and Wegovy, improve liver health independently of weight loss. Their study, published in Cell Metabolism, used mouse models and advanced technologies to explain the mechanisms behind the liver benefits of these drugs, which were originally developed to treat diabetes but have gained prominence for their weight-loss effects. This research addresses a key question in hepatology, revealing that GLP-1s can enhance liver function even in patients who do not experience significant weight reduction. The findings are particularly significant for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease that can progress to cirrhosis or liver cancer. Wegovy recently became the first pharmaceutical treatment conditionally approved for MASH, marking a milestone in managing this previously untreatable condition. The study challenges previous assumptions by demonstrating that the liver improvements are not solely tied to weight loss, which could encourage clinicians and patients to continue GLP-1 therapy for liver health benefits regardless of changes on the scale. MASH is a subset of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects roughly one-quarter of Canadian adults and an estimated 1.3 billion people worldwide as of 2023. This number is expected to rise to 1.8 billion by 2050, driven by global increases in obesity and metabolic disorders. Approximately 20 percent of MASLD patients develop MASH, which carries a high risk of serious liver complications. The new research from Dr. Daniel Drucker’s team builds on earlier evidence suggesting GLP-1 drugs may offer therapeutic benefits for liver disease, providing a clearer understanding of their mode of action and reinforcing their potential role in managing this growing public health challenge.